MLV & Co.

Analysts at MLV & Co. initiated coverage on SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) with a Buy rating. The target price for SciClone Pharmaceuticals is set to $15. SciClone Pharmaceuticals shares have gained 78.29 percent over the past 52 weeks, while the S&P 500 index has surged 7.17...

Analysts at MLV & Co. initiated coverage on Just Energy Group, Inc. Ordinary Shares (Canada) (NYSE: JE) with a Buy rating. The target price for Just Energy Group is set to $7. Just Energy Group shares have dropped 35.80 percent over the past 52 weeks, while the S&P 500 index has surged 10....

MLV & Co. initiated coverage on Garrison Capital Inc (NASDAQ: GARS) with a Buy rating. The target price for Garrison Capital is set to $15.50. Garrison Capital shares have gained 5.82 percent over the past 52 weeks, while the S&P 500 index has surged 11.85 percent in the same period....

Analysts at MLV & Co. initiated coverage on Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) with a Hold rating, according to sources. The target price for Intercept Pharmaceuticals is set to $273. Intercept Pharmaceuticals shares have dropped 32.30% over the past 52 weeks, while the S&P 500...

MLV & Co. initiated coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Buy rating. The target price for Acorda Therapeutics is set to $58. Acorda Therapeutics shares have gained 8.31% over the past 52 weeks, while the S&P 500 index has surged 13.04% in the same period. Acorda...

A recent report by MLV & Co looked at tenant presence in shopping malls. Analysts ranked the top companies growing their mall presence based on a Tenant Sentiment Index (TSI). The companies were rated on a scale of 1-10 based on their demand for space in shopping malls. Here are some of the...

Analysts at MLV & Co. initiated coverage on Ashford (NYSEMKT: AINC) with a Buy rating. The target price for Ashford is set to $110. Ashford's shares closed at $87.00 in after-hours trading.

Analysts at MLV & Co. initiated coverage on Evoke Pharma (NASDAQ: EVOK) with a Buy rating. The target price for Evoke Pharma is set to $12.50. Evoke Pharma shares have dropped 31.96% over the past 52 weeks, while the S&P 500 index has gained 14.72% in the same period. Evoke Pharma's...

MLV & Co. initiated coverage of The GEO Group Inc (NYSE: GEO) Tuesday with a Buy rating and $46 price target. Analysts Ryan Meliker and Michael B. Kodesch believed "the company offers a very compelling story that includes a strong operating free cash flow, an attractive common dividend...

MLV & Co. initiated coverage on shares of Geo Group (The) (NYSE: GEO) with a Buy rating. The target price for Geo Group is set to $46. Geo Group shares have gained 4.51% over the past 52 weeks, while the S&P 500 index has surged 9.13% in the same period. Geo Group's shares rose 1.79% to...

In a report published Tuesday, MLV & Co. analyst Chad Mabry downgraded the rating on Energy XXI Limited (NASDAQ: EXXI) from Buy to Hold, and removed the $34.00 price target. In the report, MLV & Co noted, “With fiscal 2014 in the books, we're rolling our NAV forward to fiscal 2015....

In a report published Tuesday, MLV & Co. analyst George B. Zavoico reiterated a Hold rating and $5.00 price target on Cytokinetics (NASDAQ: CYTK). In the report, MLV & Co noted, “Over the weekend, results of the international, randomized, double-blind Phase III PARADIGM-HF trial of LCZ696...

In a report published Friday, MLV & Co analyst George B. Zavoico reiterated a Buy rating and $7.00 price target on XOMA (NASDAQ: XOMA). In the report, MLV & Co noted, “Yesterday afternoon, after markets closed, XOMA Corp. reported 2Q:14 results and updated clinical progress of gevokizumab,...

In a report published Wednesday, MLV & Co. analyst Ryan Meliker reiterated a Buy rating and $45.00 price target on American Campus Communities (NYSE: ACC). In the report, MLV & Co noted, “ACC reported solid 2Q results that included a clean $0.02 beat on FFOM vs. consensus and carried the...

In a report published Friday, MLV & Co. analyst Chad Mabry reiterated a Buy rating and $86.00 price target on Carrizo Oil & Gas (NASDAQ: CRZO). In the report, MLV & Co noted, “We hosted CRZO management for investor meetings in Portland and Seattle earlier this week. Significant client...